Literature DB >> 34907706

The benefits of ascorbate to protect healthy cells in the prevention and treatment of oncological diseases.

Pavel Klener1, Matthew Scott Alexander2, Joseph John Cullen2, Vera Stejskal3, Jiri Sliva4, Lucie Kotlarova5, Pavel Kostiuk6, Zdenek Prochazka6, Marta Kucerova7.   

Abstract

Health status is determined by the balance of oxidants and antioxidants which protects healthy cells against the threat of internal and external risk factors. Antioxidants such as ascorbate (vitamin C, ascorbic acid) are of fundamental importance in this respect. Ascorbate neutralizes potential damage caused by cellular oxidative stress which may be the greatest risk of damage to healthy tissue. Cellular oxidative stress is mediated by external factors (e.g. psychological stress, physical exertion, drugs, various diseases, environmental pollution, preservatives, smoking, and alcohol) and internal factors (products of cellular metabolism including reactive oxygen species). When the products of oxidative stress are not sufficiently neutralized, healthy cells are at risk for both mitochondrial and DNA damage. In the short term, cell function may deteriorate, while an increased production of proinflammatory cytokines over time may lead to the development of chronic inflammatory changes and diseases, including cancer. Although pharmaceutical research continues to bring effective chemotherapeutic agents to the market, a limiting factor is often the normal tissue and organ toxicity of these substances, which leads to oxidative stress on healthy tissue. There is increasing interest and imperative to protect healthy tissues from the negative effects of radio-chemotherapeutic treatment. The action of ascorbate against the development of oxidative stress may justify its use not only in the prevention of carcinogenesis, but as a part of supportive or complementary therapy during treatment. Ascorbate (particularly when administered parentally at high doses) may have antioxidant effects that work to protect healthy cells and improve patient tolerability to some toxic radio-chemotherapy regimens. Additionally, ascorbate has demonstrated an immunomodulatory effect by supporting mechanisms essential to anti-tumor immunity. Intravenous administration of gram doses of vitamin C produce high plasma levels immediately, but the levels drop rapidly. Following oral vitamin C administration, plasma levels increase slowly to relatively low values, and then gradually decay. With an oral liposomal formulation, significantly higher levels are attainable than with standard oral formulations. Therefore, oral administration of liposomal vitamin C appears to be an optimal adjunct to intravenous administration. In this review, the basic mechanisms and clinical benefits of ascorbate as an antioxidant that may be useful as complementary therapy to chemotherapeutic regimens will be discussed.

Entities:  

Keywords:  Ascorbic acid; Cancer; Complementary therapy; Intravenous vitamin C; Liposomal vitamin C; Oxidative stress; Vitamin C

Year:  2020        PMID: 34907706     DOI: 10.32725/jab.2020.003

Source DB:  PubMed          Journal:  J Appl Biomed        ISSN: 1214-021X            Impact factor:   1.797


  68 in total

1.  Estimation of H2O2 gradients across biomembranes.

Authors:  F Antunes; E Cadenas
Journal:  FEBS Lett       Date:  2000-06-16       Impact factor: 4.124

Review 2.  Ascorbic acid: chemistry, biology and the treatment of cancer.

Authors:  Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Biochim Biophys Acta       Date:  2012-06-20

3.  Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues.

Authors:  Qi Chen; Michael Graham Espey; Murali C Krishna; James B Mitchell; Christopher P Corpe; Garry R Buettner; Emily Shacter; Mark Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-12       Impact factor: 11.205

4.  Hydrogen peroxide metabolism and sensing in human erythrocytes: a validated kinetic model and reappraisal of the role of peroxiredoxin II.

Authors:  Rui Benfeitas; Gianluca Selvaggio; Fernando Antunes; Pedro M B M Coelho; Armindo Salvador
Journal:  Free Radic Biol Med       Date:  2014-06-18       Impact factor: 7.376

Review 5.  Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.

Authors:  Risto S Cvetković; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Treatment of Pancreatic Cancer with Pharmacological Ascorbate.

Authors:  John A Cieslak; Joseph J Cullen
Journal:  Curr Pharm Biotechnol       Date:  2015       Impact factor: 2.837

Review 7.  Doxorubicin cardiomyopathy.

Authors:  Kanu Chatterjee; Jianqing Zhang; Norman Honbo; Joel S Karliner
Journal:  Cardiology       Date:  2009-12-11       Impact factor: 1.869

8.  The effect of ascorbic acid on production of human interferon and the antiviral activity in vitro.

Authors:  H Dahl; M Degré
Journal:  Acta Pathol Microbiol Scand B       Date:  1976-10

9.  Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells.

Authors:  C D Chiang; E J Song; V C Yang; C C Chao
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

10.  Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo.

Authors:  Qi Chen; Michael Graham Espey; Andrew Y Sun; Je-Hyuk Lee; Murali C Krishna; Emily Shacter; Peter L Choyke; Chaya Pooput; Kenneth L Kirk; Garry R Buettner; Mark Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-14       Impact factor: 11.205

View more
  1 in total

1.  Comparative Analysis of the Pharmacological Activity of Bis(3,5-di-Tert-Butyl-4-Hydroxyphenylthiolate)Dimethylol in Different Modes of Administration on a Mouse Model of Melanoma B16 Tumor Growth.

Authors:  M A Dodokhova; I M Kotieva; A V Safronenko; M S Alkhusein-Kulyaginova; N V Sukhorukova; V M Kotieva; E M Kotieva; S I Starostin; D B Shpakovsky; E A Nikitin; E R Milaeva
Journal:  Bull Exp Biol Med       Date:  2022-10-10       Impact factor: 0.737

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.